Improved management and 10-year outcomes in diabetic kidney disease in routine clinical care
DOI:
https://doi.org/10.15277/bjdvd.2015.002Abstract
Aim: To examine the impact of service re-design on management and 10-year outcomes in diabetic kidney disease in a real world setting.
Methods: We established a highly structured, nurse-led diabetic kidney clinic to deliver consistent evidence-based care processes (blood pressure control (BP), glycaemic control (HbA1c), renin-angiotensin-aldosterone (RAAS) blockade, lipid-lowering therapy and smoking cessation) and assessed impact on death, doubling of serum creatinine, new end-stage renal disease (ESRD), new cardiovascular (CV) events and decline in estimated glomerular filtration rate (eGFR).
Results: There were 261 patients in the 10-year cohort: 9 casenotes were missing and 23 had been destroyed. Our analysis is based on 229 patients for whom we had data (1,799 patient-years of follow-up): 28 (12%) had new CV events, 22 (10%) progressed to ESRD (16 dialysis, 3 conservative treatment, 3 transplant) and 87/229 (38%) died. At last assessment, mean BP was 129/70 mmHg, HbA1c 59 mmol/mol (7.6%) and LDL-cholesterol 1.81 mmol/L. Mean rate of eGFR decline was 0.15 mL/min/month. Expressed per 100-patient-years, mortality 4.83, CV events 1.56, doubling serum creatinine 1.72, and ESRD 1.22 compare favourably with landmark trials.
Conclusions: A highly structured, nurse-led, diabetic kidney clinic can translate consistent evidence-based care processes into favourable 10-year outcomes in routine clinical care.
References
Hovind P, Tarnow L, Rossing P, et al. Predictors for the development of microalbuminuria and macroalbuminuria in patients with type 1 diabetes: inception cohort study. BMJ 2004;328:1105. http://dx.doi.org/10.1136/bmj.38070.450891.FE
Wang SL, Head J, Stevens L, Fuller JH. Excess mortality and its relation to hypertension and proteinuria in diabetic patients. The World Health Organisation Multinational Study of Vascular Disease in Diabetes. Diabetes Care 1996;19:305-12. http://dx.doi.org/10.2337/diacare.19.4.305
Diabetes Control and Complications Trial Research Group. The effect of the intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977-86. http://dx.doi.org/10.1056/NEJM199309303291401
UKPDS Study Group. Intensive blood glucose control with sulphonylureas of insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes mellitus. Lancet 1998;352:837-853.
OhkuboY, Kishikawa H, Araki E, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract 1995;28:103-17. http://dx.doi.org/10.1016/0168-8227(95)01064-K
UKPDS Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998;317:703-13. http://dx.doi.org/10.1136/bmj.317.7160.703
Lewis EJ, Hunsicker LG, Bain RP, Rohde RD, for the Collaborative Study Group. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med 1993;329:1456-62. http://dx.doi.org/10.1056/NEJM199311113292004
Gaede P, Vedel P, Parving H, Pederson O. Intensified multifactorial intervention in patients with type 2 diabetes and microalbuminuria: the Steno type 2 randomised study. Lancet 1999;353:617-22. http://dx.doi.org/10.1016/S0140-6736(98)07368-1
Parving HH, Lehnert H, Brochner-Mortenson B, et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001;345:870-8. http://dx.doi.org/10.1056/NEJMoa011489
Lewis EJ, Hunsicker, LG, Clarke WR, et al. Renoprotective effect of the antagiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001;345:851-60. http://dx.doi.org/10.1056/NEJMoa011303
Brenner BM, Cooper ME, Zeeuw D, Keane WF. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345:861-9. http://dx.doi.org/10.1056/NEJMoa011161
Mogensen CE, Cooper ME. Diabetic renal disease: from recent studies to improved clinical practice. Diabet Med 2004;21:4-17. http://dx.doi.org/10.1111/j.1464-5491.2004.01121.x
ADA (American Diabetes Association). Nephropathy in Diabetes (Position Statement). Diabetes Care 2004;27(Suppl.1):S79-S83. http://dx.doi.org/10.2337/diacare.27.2007.S79
National Institute for Clinical Excellence. Management of type 2 diabetes. Renal disease – prevention and early management. Inherited Clinical Guideline F. London, NICE, 2005.
Renal Association. Treatment of adults and children with renal failure: standards and audit measures, 3rd Edition, 2002. www.renal.org/Standards/RenalStandards_2002b.pdf
Rigalleau MD, Lasseur C, Perlemoine C, et al. Estimation of glomerular filtration rate in diabetic subjects. Cockcroft Gault or Modification of Diet in Renal Disease study Equation? Diabetes Care 2005;28:838-43. http://dx.doi.org/10.2337/diacare.28.4.838
HOPE (Heart Outcomes Prevention Evaluation) Study Investigators. MICRO_HOPE Substudy. Effects of Ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus. Lancet 2000; 355:253-59. http://dx.doi.org/10.1016/S0140-6736(99)12323-7
Published
Issue
Section
License
Publish & Transfer of Copyright Agreement
For the mutual benefit and protection of the Author and the Journal Owner/Publisher it is necessary that the Author provides formal written Consent to Publish and Transfer of Copyright before publication of the Work.
